Astrazeneca (AZN) Accounts Payables (2009 - 2026)
Astrazeneca (AZN) posted quarterly Accounts Payables of $22.9 billion for Q2 2026, down 4.56% year-over-year from $24.0 billion in Q2 2025, and up 201.72% quarter-over-quarter from -$22.5 billion in Q1 2026.
Astrazeneca (AZN) Accounts Payables (2009 - 2026) Analysis & Trends
Astrazeneca's Accounts Payables history runs 18 years deep, the most recent figure standing at $22.9 billion for Q2 2026.
- In Q2 2026, Accounts Payables fell 4.56% year-over-year to $22.9 billion; the TTM figure through Jun 2026 stood at $22.9 billion (down 4.56% YoY), while the FY2025 annual figure was $25.3 billion, up 12.53% from the prior year.
- Accounts Payables for Q2 2026 stood at $22.9 billion, up from -$22.5 billion in the prior quarter.
- The five-year high for Accounts Payables was $25.3 billion in Q4 2025, with the low at -$25.0 billion in Q3 2025.
- The 5-year median for Accounts Payables is -$18.5 billion (2022), against an average of -$6.0 billion.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables plunged 30.17% in 2022, then surged 217.22% in 2025.
- Astrazeneca's Accounts Payables stood at $19.0 billion in 2022, then gained by 17.51% to $22.4 billion in 2023, then climbed by 0.41% to $22.5 billion in 2024, then advanced by 12.53% to $25.3 billion in 2025, then retreated by 9.44% to $22.9 billion in 2026.
- Business Quant data shows AZN's Accounts Payables at $22.9 billion in Q2 2026, -$22.5 billion in Q1 2026, and $25.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.89 Bn |
| Mar 31, 2026 | -22.51 Bn |
| Dec 31, 2025 | 25.28 Bn |
| Sep 30, 2025 | -25.03 Bn |
| Jun 30, 2025 | 23.99 Bn |
| Mar 31, 2025 | -22.54 Bn |
| Dec 31, 2024 | 22.47 Bn |
| Sep 30, 2024 | -21.68 Bn |
| Jun 30, 2024 | -20.46 Bn |
| Mar 31, 2024 | -19.70 Bn |
| Dec 31, 2023 | 22.37 Bn |
| Sep 30, 2023 | -20.54 Bn |
| Jun 30, 2023 | -19.74 Bn |
| Mar 31, 2023 | -19.21 Bn |
| Dec 31, 2022 | 19.04 Bn |
| Sep 30, 2022 | -17.69 Bn |
| Jun 30, 2022 | -17.82 Bn |
| Mar 31, 2022 | -17.86 Bn |
| Dec 31, 2021 | 18.94 Bn |
| Sep 30, 2021 | -18.66 Bn |